Abstract
Purpose
New multimodality treatment approaches for prostate cancer require multidisciplinary management of patients. We aimed to assess the current practices of multidisciplinarity and their possible implications in treatment management in Switzerland.
Methods
In a survey, urologists and medical oncologists in Switzerland were asked to include at least 25 or 15 consecutive patients with the diagnosis of prostate cancer, respectively. Information about treatment patterns and multidisciplinary parameters of these patients was collected retrospectively.
Results
Thirty-seven urologists and 20 oncologists from the French- and German-speaking parts of Switzerland representing 7 out of 11 non-university tertiary centres and 20/10 % of all office-based urologists/oncologists in Switzerland collected data on 1,184 patients. Sixty-five percent of the office-based (16/24 urologists; 6/10 oncologists) and 95 % of the hospital-based (10/11 urologists; 8/8 oncologists) physicians participate in multidisciplinary tumour boards (MTBs). However, only 1.5 % of patients with a new diagnosis of prostate cancer (13 of 883) are discussed at a MTB. Overall, second opinions at diagnosis are requested in 23 % of patients, mainly from radiation oncologists (8.4 %) or fellow urologists (7.4 %). Second opinions are more often requested by urologists who participate at MTBs and in case of advanced stage.
Conclusions
Participation at MTBs is high among Swiss urologists and oncologists in private practice and at non-university tertiary centers. In spite of that only a small minority of patietns with prostate cancer are presented at MTBs.
Similar content being viewed by others
References
Picard JC, Golshayan AR, Marshall DT, Opfermann KJ, Keane TE (2012) The multi-disciplinary management of high-risk prostate cancer. Urol Oncol 30:3–15
Lu-Yao GL, Albertsen PC, Moore DF et al (2009) Outcomes of localized prostate cancer following conservative management. JAMA 302:1202–1209
Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123
Payne HA, Gillatt DA (2007) Differences and commonalities in the management of locally advanced prostate cancer: results from a survey of oncologists and urologists in the UK. BJU Int 99:545–553
Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572–583
Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990–2007. World J Urol 26:211–218
Cooperberg MR, Broering JM, Kantoff PW, Carroll PR (2007) Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178:S14–S19
Cooperberg MR, Moul JW, Carroll PR (2005) The changing face of prostate cancer. J Clin Oncol 23:8146–8151
Jeldres C, Suardi N, Walz J et al (2008) Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. Eur Urol 54:107–116
Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154
de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005
Ruhstaller T, Roe H, Thurlimann B, Nicoll JJ (2006) The multidisciplinary meeting: an indispensable aid to communication between different specialities. Eur J Cancer 42:2459–2462
Ko C, Chaudhry S (2002) The need for a multidisciplinary approach to cancer care. J Surg Res 105:53
Boyle FM, Robinson E, Dunn SM, Heinrich PC (2005) Multidisciplinary care in cancer: the fellowship of the ring. J Clin Oncol 23:916–920
Valicenti RK, Gomella LG, El-Gabry EA et al (2000) The multidisciplinary clinic approach to prostate cancer counseling and treatment. Semin Urol Oncol 18:188–191
Gomella LG, Lin J, Hoffman-Censits J et al (2010) Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J Oncol Pract 6:e5–e10
Valdagni R, Albers P, Bangma C et al (2011) The requirements of a specialist prostate cancer unit: a discussion paper from the European School of Oncology. Eur J Cancer 47:1–7
Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131
Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M (2010) Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 58:831–835
Bolla M, de Reijke TM, Van Tienhoven G et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360:2516–2527
Ganswindt U, Stenzl A, Bamberg M, Belka C (2008) Adjuvant radiotherapy for patients with locally advanced prostate cancer—a new standard? Eur Urol 54:528–542
Kibel AS (2005) An interdisciplinary approach to treating prostate cancer. Urology 65(6 Suppl):13–18
Hamilton AS, Albertsen PC, Johnson TK et al (2011) Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 107:576–584
Cooperberg MR, Broering JM, Litwin MS et al (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171:1393–1401
Aizer AA, Paly JJ, Zietman AL et al (2012) Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 30:3071–3076
Acknowledgments
This study was supported by an unrestricted grant from Sanofi-Aventis (Suisse) SA, Meyrin, Switzerland.
Conflict of interest
Richard Cathomas has a consultant role for Janssen Cilag and Sanofi-Aventis. Silke Gillessen has a consultant role for Novartis, Janssen Cilag, Pfizer, Sanofi-Aventis, GSK, and Millennium. All other authors report no conflicts of interest. We hereby state that we have full control of all data and we allow the journal to review the data if deemed necessary.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Strebel, R.T., Sulser, T., Schmid, HP. et al. Multidisciplinary care in patients with prostate cancer: room for improvement. Support Care Cancer 21, 2327–2333 (2013). https://doi.org/10.1007/s00520-013-1791-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-013-1791-x